Derynck Mika K 4

What Happened

• Mika K. Derynck, a non-employee director of Enliven Therapeutics, was granted a derivative equity award on 2026-02-12 covering 17,126 shares. The filing reports a per-share price of $0.00 and a total reported value of $0 (this reflects reporting of a derivative award rather than an open-market purchase or sale). The award is subject to vesting conditions (see footnote).

Key Details

• Transaction date: 2026-02-12; Form 4 filed: 2026-02-17.
• Transaction type/code: Grant / Award (A); amount: 17,126 shares; reported price: $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: 100% of the shares subject to the option vest on the earlier of (i) the first anniversary of the 2026 annual meeting or (ii) the date of the 2027 annual meeting, provided the reporting person continues as a non-employee director through the applicable vesting date.
• Timeliness: The Form 4 was filed five days after the reported transaction date—after the typical 2-business-day deadline for Form 4s—so this filing appears late.

Context

• This was an equity award to a director (compensation/retention), not an open-market buy or sale. Such grants are routine for directors and do not by themselves signal a buy/sell opinion of the market.
• The award is a derivative/option-type grant subject to vesting; the shares are not yet vested or freely tradable until the vesting condition is met. There is no indication the shares were immediately sold or transferred.